In briefBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7344.994/b (Published 27 April 2002) Cite this as: BMJ 2002;324:994
FDA demands warning label on rofecoxib: The US Food and Drug Administration has ordered drug manufacturer Merck to put a warning label on the cyclo-oxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx) stating that it can raise blood pressure and may increase the risk of heart attacks; the move follows research findings on the drug's side effects (BMJ 2001;323:471).
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial